It is not known to be marketed anywhere in the world.[3]
References
^Fach, WA; Starke, E; Becker, HJ (1992). "Duration of the effect and dose-response relationship of ridazolol in patients with coronary heart disease". Zeitschrift für Kardiologie. 81 (6): 320–5.
PMID1353933.
^Rommel, Th.; Demisch, L. (1994). "Influence of chronic ?-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension". Journal of Neural Transmission. 95 (1): 39–48.
doi:
10.1007/BF01283029.
PMID7857585.
S2CID31936176.
It is not known to be marketed anywhere in the world.[3]
References
^Fach, WA; Starke, E; Becker, HJ (1992). "Duration of the effect and dose-response relationship of ridazolol in patients with coronary heart disease". Zeitschrift für Kardiologie. 81 (6): 320–5.
PMID1353933.
^Rommel, Th.; Demisch, L. (1994). "Influence of chronic ?-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension". Journal of Neural Transmission. 95 (1): 39–48.
doi:
10.1007/BF01283029.
PMID7857585.
S2CID31936176.